| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 公司是我国再生医学领域领先企业，主营业务为生物再生材料的研发、生产与销售，主要产品包括口腔修复膜、生物膜等软组织修复材料以及骨修复材料等硬组织修复材料。公司产品主要用于临床组织再生和创伤修复，属于再生医学范畴。公司采用组织工程学技术，对动物源性的特定组织和器官进行脱细胞、病毒及病原体灭活等一系列处理后，得到具有天然组织空间结构的支架材料。公司产品具有良好的组织相容性，无免疫排斥反应，在修复病变组织或器官功能的同时，能够诱导组织再生，已广泛应用在口腔科、神经外科等领域。 依托较强的技术、品牌、渠道等综合竞争优势，公司己与北京大学口腔医院、四川大学华西口腔医院、上海交通大学医学院附属第九人民医院、天津市环湖医院、西京医院、上海长征医院等诸多国内知名三甲医院建立了良好的合作关系。2014年至2016年，公司分别实现营业收入10,530.47万元12,813.25万元和15,062.25万元，归属于母公司的净利润分别为3,366.05万元、4,249.22万元和4,547.01万元，呈现良好的发展态势。未来公司将进一步专注于再生医学领域，并致力于生物再生材料等高附加值产品的深度研发及产业化。 | ||||||||||||||||||||||||
| Main Business | 生物再生材料的研发、生产与销售。 | ||||||||||||||||||||||||
| Legal Representative | 郭焕祥 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 赵丽 | ||||||||||||||||||||||||
| Solicitors | 北京市金杜律师事务所 | ||||||||||||||||||||||||
| Auditors | 大信会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0535-6971993 | ||||||||||||||||||||||||
| Fax No | 0535-6971993 | ||||||||||||||||||||||||
| Website | www.zhbio.com | ||||||||||||||||||||||||
| ir@zhbio.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 16/05/2017 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 1.060 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.802 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 5.267 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 4.100B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |